Managed Healthcare Executive, Digital Edition, December 2010

FDA officials have set a review date of June 30, 2025, to review avutometinib in combination with defactinib to treat patients with recurrent low-grade serous ovarian cancer.

Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.

Check out this list of the top five biologics articles posted on Managed Healthcare Executive this year!

In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.

2024's top podcast episodes includes a conversation with Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits.

Take a look at this year’s top articles — one showcasing enhanced weight loss through Semaglutide use in post-menopausal women on hormonal therapy.